Abstract: Type 2 diabetes (T2D) is one of the leading causes of morbidity and mortality all over the world.Epidemiologic studies have demonstrated that the patients with obesity have increased risk of diabetes.A novel G protein coupled receptor(GPCR),GPR119,was identified and has emerged as arguably one of the most exciting targets for the treatment of T2D and obesity. In vitro and in vivo, GPR119 play a key role in modulating glucose homeostasis,food intake,weight loss.This review summarizes the research leading to the identification of GPR119 as a potential drug target for T2D and related metabolic disorders.In addition,an overview of the recent progress made in the discovery of orally active GPR119 agonists is provided.

Key words: GPR119, agonist, G protein-coupled receptor, Type 2 diabetes, Obesity